← All trials
NCT05249335
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2022
- Primary completion
- Feb 29, 2024
- Completion date
- Feb 29, 2024
- First posted
- Feb 21, 2022
- Last posted
- Feb 21, 2022
- Enrollment
- 256
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Pharmbio KoreaLead sponsor
- Hallym UniversityOverall official - principal investigator
- Incheon St.Mary's HospitalOverall official - principal investigator
- Kyung Hee UniversityStudy chair
- Wonkwang UniversityOverall official - principal investigator
- Kyung Hee UniversityOfficial
- Wonkwang UniversityOfficial
- Hallym UniversityOfficial
- Incheon St.Mary's HospitalOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.